Experimentation with two more pancreatic cancer cell lines (Panc-1, PL-5) showed similar improvements in their gemcitabine sensitivity following GPRC5A knockdown (Supplementary Figures S4A–F). This evidence concerns the gene GPRC5A and pancreatic neoplasm.